Ibandronic acid tablets
Indication
adjuvant treatment of early breast cancer in postmenopausal women with a high risk of recurrence (unlicensed indication)
Amber level 0
Brand:
Bondronat
Nice TA:
Commissioning responsibility:
CCG (HRG included)
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: